Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus

Lupus

Volumn 15, Issue 10, 2006, Pages 671-674

  Bernatsky, Sasha ^a   Pineau, C A ^a   Lee, J L ^a   Clarke, A E ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Headache; Raynaud's syndrome; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; LUPUS ANTICOAGULANT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE DURATION; FEMALE; GENERAL HOSPITAL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; VASOSPASM;

ADULT; COHORT STUDIES; FEMALE; HEADACHE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREVALENCE; RAYNAUD DISEASE; REGRESSION ANALYSIS; SEROTONIN AGONISTS;

EID: 33750589492     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306069997     Document Type: Article

References (25)

1. Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol 1992; 239: 39-42.
2. Montalban J, Cervera R, Font J et al. Lack of association between anti-cardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992; 42: 681-682.
3. Whitelaw D, Hugo F, Spangenberg J, Rickman R. Headaches in patients with systemic lupus erythematosus: a comparative study. Lupus 2004; 13: 501-505.
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet 2001; 358: 1668-1675.
5. Koh KK, Roe IH, Lee MM, Cho SK, Kim SS. Variant angina complicating ergot therapy of migraine. Chest 1994; 105: 1259-1260.
6. Sfikakis P, Mitsikostas D, Manoussakis M, Foukaneli D, Moutsopoulos H. Headache in systemic lupus erythematosus: a controlled study. Br J Rheumatology 1998; 37: 300-303.
7. Block JA, Sequeira W. Raynaud's phenomenon. The Lancet 2001; 357: 2042-2048.
8. Zahavi I, Chagnac A, Hering R, Davidovich S, Kuritzky A. Prevalence of Raynaud's phenomenon in patients with migraine. Arch Intern Med 1984; 144: 742-744.
9. Appenzeller S, Costallat LTL. Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 2004; 24: 1024-1030.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1998; 41: 751.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of SLE. Arthritis and Rheumatism 1982; 25: 1271-1277.
12. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis and Rheumatism 1988; 31: 817-825.
13. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome - Report of an international workshop. Arthritis and Rheumatism 1999; 42: 1309-1311.
14. Weder-Cisneros N, Tellez-Zenteno J, Cardiel M et al. Prevalence and factors associated with headache in patients with systemic lupus erythematosus. Cephalalgia 2004; 24: 1031-1044.
15. Levine JS, Subang R, Koh JS, Rauch J. Induction of anti-phospholipid autoantibodies by beta 2-glycoprotein I bound to apoptotic thymocytes. Journal of Autoimmunity 1998; 11: 413-424.
16. Rauch J, Janoff AS. Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 4112-4114.
17. Isenberg D, Meyrick-Thomas D, Snaith M, McKeran R, Royston J. A study of migraine in systemic lupus erythematosus. Ann Rheum Dis 1982; 41: 30-32.
18. Hottenga JJ, Vanmolkot KRJ, Kors EE et al. The 3p21.1-p21.3 hereditary vascular retinopathy locus increases the risk for Raynaud's phenomenon and migraine. Cephalalgia 2005; 25: 1168-1172.
19. Williams F, Cherkas L, Spector T, MacGregor A. A common genetic factor underlies hypertension and other cardiovascular disorders. BMC Cardiovasc Discord 2004; 4: 20.
20. Nakamura Y, Shinozaki N, Hirasawa M et al. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. Jpn Circ J 2000; 64: 239-242.
21. Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, Drosos AA. Prevalence of Raynaud's phenomenon in a healthy Greek population. Ann Rheum Dis 2000; 59: 206-210.
22. O'Keeffe ST, Tsapatsaris NP, Beetham WP Jr. Association between Raynaud's phenomenon and migraine in a random population of hospital employees. J Rheumatol 1993; 20: 1187-1188.
23. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 657-660.
24. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
25. Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001; 40: 1038-1043.